198 related articles for article (PubMed ID: 15544691)
1. An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy.
Ormaasen V; Sandvik L; Asjø B; Holberg-Petersen M; Gaarder PI; Bruun JN
HIV Med; 2004 Nov; 5(6):400-6. PubMed ID: 15544691
[TBL] [Abstract][Full Text] [Related]
2. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
[TBL] [Abstract][Full Text] [Related]
3. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM
Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
[TBL] [Abstract][Full Text] [Related]
4. The V118I mutation as a marker of advanced HIV infection and disease progression.
Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
[TBL] [Abstract][Full Text] [Related]
5. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
[TBL] [Abstract][Full Text] [Related]
6. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
7. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
[TBL] [Abstract][Full Text] [Related]
8. Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Englund JA; Raskino C; Vavro C; Palumbo P; Ross LL; McKinney R; Nikolic-Djokic D; Colgrove RC; Baker CJ;
Pediatr Infect Dis J; 2004 Jan; 23(1):15-22. PubMed ID: 14743040
[TBL] [Abstract][Full Text] [Related]
9. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.
Bossi P; Peytavin G; Ait-Mohand H; Delaugerre C; Ktorza N; Paris L; Bonmarchand M; Cacace R; David DJ; Simon A; Lamotte C; Marcelin AG; Calvez V; Bricaire F; Costagliola D; Katlama C
HIV Med; 2004 Sep; 5(5):352-9. PubMed ID: 15369510
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
11. [Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005].
Afani S A; Orellana R L; Duarte J P; Acevedo M W; Morales B O; Wolff R M; Vásquez P; Beltrán C
Rev Med Chil; 2007 Oct; 135(10):1237-44. PubMed ID: 18180829
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
[TBL] [Abstract][Full Text] [Related]
13. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
[TBL] [Abstract][Full Text] [Related]
14. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients.
Antinori A; Trotta MP; Nasta P; Bini T; Bonora S; Castagna A; Zaccarelli M; Quirino T; Landonio S; Merli S; Tozzi V; Di Perri G; Andreoni M; Perno CF; Carosi G
Antivir Ther; 2006; 11(2):233-43. PubMed ID: 16640104
[TBL] [Abstract][Full Text] [Related]
15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
16. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
17. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
[TBL] [Abstract][Full Text] [Related]
19. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
[TBL] [Abstract][Full Text] [Related]
20. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
